Compare TENB & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENB | ADPT |
|---|---|---|
| Founded | 2002 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3B | 2.3B |
| IPO Year | 2018 | 2019 |
| Metric | TENB | ADPT |
|---|---|---|
| Price | $17.92 | $14.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $32.76 | $17.78 |
| AVG Volume (30 Days) | ★ 2.4M | 2.2M |
| Earning Date | 04-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.23 | ★ 63.89 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $999,405,000.00 | $276,976,000.00 |
| Revenue This Year | $9.37 | $3.98 |
| Revenue Next Year | $7.04 | $22.72 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 11.04 | ★ 54.77 |
| 52 Week Low | $15.85 | $6.77 |
| 52 Week High | $35.69 | $20.76 |
| Indicator | TENB | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 41.27 | 53.20 |
| Support Level | $17.28 | $12.19 |
| Resistance Level | $21.25 | $17.52 |
| Average True Range (ATR) | 1.00 | 0.80 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 42.12 | 75.99 |
Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.